Down 97% From Record Highs, Is Sundial Stock a Buy Right Now?

Despite the 97% decline in Sundial stock from its record high, it remains a risky bet for long-term investors due to poor fundamentals.

| More on:

Canadian cannabis company Sundial Growers (NASDAQ:SNDL) has been among the worst performers on the bourses since the stock went public in August 2019. Soon after its initial public offer, SNDL stock was priced at a high of US$11.5 and is now trading 97% below that, at US$0.56.

Let’s see what impacted Sundial stock in the past and if it is a good contrarian buy right now.

Sundial has massively diluted shareholder wealth

A key reason for the underperformance of Sundial can be attributed to shareholder dilution. In the five-month period between September 2020 and February 2021, the company issued 1.15 billion shares to offset its cash burn and lower its debt balance.

Further, last September, Sundial disclosed it will reduce its product portfolio and liquidate low-margin items to improve the bottom line. Sundial’s revenue was impacted by COVID-19 as its sales in 2020 stood at $60.9 million, compared to $75.8 million in 2019. Due to its strategic decision to exit certain markets, Sundial’s revenue in the last 12 months stood at $47.26 million.

In Q3 of 2021, Sundial reported sales of $14.4 million, an increase of 57% on a sequential basis. The growth in revenue was due to higher retail sales and the acquisition of Inner Spirit Holdings. However, its cultivation and production revenue stood at $8.2 million in Q3 compared to $9.2 million in Q2 and $9.9 million in Q1.

Sundial has burnt $173 million from its operating activities in the last four quarters. In Q3, its cash burn was $56 million, compared to $20 million in the year-ago period. As the company continues to focus on its retail cannabis business as well as the acquisition of Alcanna, its cash burn number might increase in the near term.

Sundial ended Q3 of 2021 with $571 in cash, providing it with enough liquidity right now. However, the balance could erode swiftly if Sundial goes on an acquisition spree, resulting in further shareholder dilution.

What next for SNDL stock?

In Q4 of 2021, Wall Street expects Sundial to report sales of $13.25 million, an increase of 15.4% year over year. However, it’s also expected to end 2021 with a loss per share of $0.07 which translates to net losses of $168 million.

Now, Sundial’s revenue might increase to $625.4 million in 2022 due to the Alcanna acquisition, which is one of the largest liquor retailers in Canada. Further, Alcanna’s subsidiary, Nova Cannabis, owns and operates 78 retail outlets across several provinces.

SNDL stock is valued at a forward price to sales multiple of less than three, which is quite reasonable given its growth forecasts. Despite falling sales, Sundial’s focus on selling high-margin products allowed the company to report an adjusted EBITDA of $10.5 million in Q3 of 2021. Analysts expect SNDL to break even on an adjusted basis by the end of 2022.

The Foolish takeaway

Sundial remains a high-risk bet considering the possibility of further shareholder dilution and less than impressive revenue growth. I believe there are far better pot stocks you can buy right now, given the risk-reward profile of Sundial.

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

More on Cannabis Stocks

four people hold happy emoji masks
Dividend Stocks

Wary of Mining Companies? A Lower-Risk Way to Get in on the Gold and Silver Surge

Frenco-Nevada (TSX:FNV) stock might be a wiser way to play the run in gold prices this year.

Read more »

Cannabis smoke
Cannabis Stocks

Have Cannabis Stocks Totally Gone Up in Smoke?

Let's dive into whether Canadian cannabis stocks are still investable, and what investors should make of the recent volatility in…

Read more »

Researcher works in hemp field
Cannabis Stocks

1 Undervalued Cannabis Stock to Buy and Hold Over the Next Decade

Green Thumb is a beaten-down cannabis stock that trades at a compelling valuation in September 2025.

Read more »

Researcher works in hemp field
Cannabis Stocks

Pot Stocks Rallied Hard in August: Is There More to Come?

Tilray Brands (TSX:TLRY) and the broad basket of pot stocks could heat up from here.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Canopy Growth Stock Jumped 30% Last Month: What’s Going on?

Canopy Growth (TSX:WEED) stock is picking up traction again, making it an enticing weed play to buy on strength.

Read more »

A cannabis plant grows.
Cannabis Stocks

These Threats Facing Canopy Growth Stock Could Justify Selling it

Let's dive into whether Canopy Growth (TSX:WEED) is a top stock investors should buy right now after its recent dip…

Read more »

A person holds a small glass jar of marijuana.
Stocks for Beginners

This BioCannabis Firm Could Explode with Product Approval

This cannabis stock used to be a major name, so where does it stand now?

Read more »

Medicinal research is conducted on cannabis.
Stocks for Beginners

This TSX Health-Care Stock Is a Long-Term Buy for Patient Investors

This TSX stock continues to be one of the best long-term opportunities, if you're patient.

Read more »